DDInter1289 DDInter1435
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Nicotinamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Carbamazepine
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Nicotinamide may cause a minor interaction that can limit clinical effects when taken with Carbamazepine
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Nicotinamide may lead to a major life threatening interaction when taken with Teriflunomide
Nicotinamide may lead to a major life threatening interaction when taken with Leflunomide